Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials

Cancer

Volumn 83, Issue 6, 1998, Pages 1142-1152

  Buzdar, Aman U ^a   Jonat, Walter ^b   Howell, Anthony ^c   Jones, Stephen E ^d   Blomqvist, Carl P ^e   Vogel, Charles L ^f   Eiermann, Wolfgang ^g   Wolter, Janet M ^h   Steinberg, Mark ⁱ   Webster, Alan ⁱ   Lee, David ⁱ  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f Compreh Cancer Research Group Inc ^*  (United States)

^g Frauenklinik Vom Roten Kreuz ^*  (Germany)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Advanced breast carcinoma; Anastrozole; Aromatase inhibitor; Megestrol acetate; Postmenopausal

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; MEGESTROL ACETATE;

ADULT; AGED; AGING; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VAGINA BLEEDING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEGESTROL; NITRILES; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TRIAZOLES;

EID: 0032530988     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5     Document Type: Article

References (19)

1. Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23(Suppl 9):10-20.
2. Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol 1996;23(Suppl 9):33-8.
3. Buzdar A, Jonat W, Howell A, Jones S-E, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
4. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
5. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996;73:543-8.
6. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997;79:730-9.
7. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
8. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
9. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
10. Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blarney RW. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989;25:469-75.
11. Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996;9:292-306.
12. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 1996;77:2503-13.
13. Smith I, Dombernowsky P, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) (Abstract PP-8-3|. Eur J Cancer 1996;32A: (Suppl 2):49.
14. Goss P, Wine E, Tannock I, Schwartz IH, Kremer AB, and study group. Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen [Abstract 542]. Proc ASCO 1997;16:155a.
15. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens [Abstract 544]. Proc ASCO 1997;16:156a.
16. Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [Abstract 543]. Proc ASCO 1997;16: 155a.
17. Muss HB, Wells B, Paschold EH, Black WR, Cooper MR, Capizzi RL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6: 1098-106.
18. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-805.
19. Michaud LB, Knoche AJ, Abbott B, Buzdar AU, Tashima C. Efficacy of anastrozole (Arimidex) in a consecutive series of advanced breast cancer patients: M. D. Anderson Cancer Center (MDACC) experience [Abstract 641]. Proc ASCO 1997; 16:183a.